Luigi Grasso

Luigi Grasso

Luigi Grasso, Ph.D. is the Sr Vice President, Chief Scientific Officer and co-founder of Navrogen Inc. Prior to co-founding Navrogen, he was Vice President, CSO and co-founder of Morphotek Inc., a private biopharmaceutical company specializing in the development of antibody-based therapies for cancer, which was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained at Morphotek as VP and CSO and oversaw the global R&D of antibody and next gen antibody-based products for the treatment of various cancer indications. Prior to co-founding Morphotek, he was Associate Director of Research at Magainin Pharmaceuticals Inc where he oversaw the development […]

read more

Nicholas C. Nicolaides

Nicholas C. Nicolaides, Ph.D. is the President, Chief Executive Officer and co-founder of Navrogen Inc. Prior to co-founding Navrogen, he was President, CEO and co-founder of Morphotek Inc., a private biopharmaceutical company specializing in the development of protein and antibody therapeutics through the use of a proprietary gene evolution technology. Morphotek was acquired by Eisai, Co. Ltd. in 2007. From 2007 to 2018, he remained President and CEO of Morphotek as it operated as an autonomous subsidiary of Eisai. Prior to co-founding Morphotek, he was Director of R&D at Magainin Pharmaceuticals Inc. He is a trained molecular geneticist and has authored over […]

read more